Generation and Characterization of an Anti-Idiotype Monoclonal Antibody Related to GM3(NeuGc) Ganglioside

Hybridoma and Hybridomics

Volumn 22, Issue 5, 2003, Pages 307-314

  Rodríguez, Mabel ^a   Llanes, Leticia ^a   Pérez, Alexis ^a   Pérez, Rolando ^a   Vázquez, Ana María ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; GANGLIOSIDE GM3; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN G1; KEYHOLE LIMPET HEMOCYANIN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CELL HYBRIDIZATION; CELL LINE; CONTROLLED STUDY; GENE FUSION; IMMUNIZATION; INJECTION; MOUSE; MOUSE STRAIN; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALIA; GALLUS GALLUS; MURINAE;

EID: 0344825770     PISSN: 15368599     EISSN: None     Source Type: Journal    
DOI: 10.1089/153685903322538836     Document Type: Article

References (36)

1. Hakomori S: Glycosphingolipids in cellular interaction, differentiation and oncogenesis. Ann Rev Biocem 1985;45:2405-2414.
2. Irie RF and Ravindranath MH: Gangliosides as target for monoclonal antibodies therapy of cancer. In: Therapeutic Monoclonal Antibodies. Borrebaeck CAK, and Larrick GW (Eds.). M. Stockom Press, New York, 1990, pp. 75-94.
3. Irie A and Suzuki A: CMP-N-acetylneuraminic acid hydroxylase is exclusively inactive in humans. Biochem Biophys Res Commun 1998;248:330-333.
4. Schauer R, Malykin YN, Krisch B, Gollub M, and Shaw L: Biosynthesis and biology of N-glycolylneuraminic acid. In: Sialobiology and Other Novel Forms of Glycosylation. Inoue Y, Lee YC, and Troy FA (Eds.). Gakushin Publishing Company, Osaka, 1999, pp. 17-27.
5. Malykh YN, Schauer R, and Shaw L: N-glycolylneuraminic acid in human tumours. Biochimie 2001;83:623-634.
6. Livingston PO: Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside KLH conjugate vaccines. Immunol Rev 1995;145:147-166.
7. Livingston PO: Augmenting the immunogenicity of carbohydrate tumor antigens. Semin Cancer Biol 1995;6:357-366.
8. Livingston PO, and Ragupathi G: Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future. Cancer Immunol. Immunother. 1997;45:10-19.
9. Jerne NK: Toward a network theory of the immune system. Ann. Immunol. (Paris) 1974;125C:373-389.
10. McCaffery M, Yao T-J, Willians L, Livingston PO, Houghton AN, and Chapman PB: Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adyuvant. Clin Cancer Res 1996;2:679-686.
11. Foon KA, Sen G, Hutchins L, Kashala OL, Baral R, Banerjee M, Chakraborty M, Garrison J, Reisfeld RA, and Battacharya-Chaterjee M: Antibody response in melanoma patients immunized with an anti-idiotype mimicking disialoganglioside GD2. Clin Cancer Res 1998;4:1117-1124.
12. Yao T-J, Meyers M, Livingston PO, Houghton AN, and Chapman PB: Immunization of melanoma patients with BEC2. Keuhole limpet hemocyanine plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res 1999;5:77-81.
13. Grant SC, Kris MG, Houghton AN, and Chapman PB: Lung survival of patients with small cell lung cancer after adjuvant treatment with anti-idiotypic antibody BEC2 plus bacilluus Calmette-Guérin. Clin Cancer Res 1999;5:1319-1323.
14. Foon KA, Lutzky J, Baral RN, Yannelli, JR, Hutchins L, Teitelbaum A, Kashala OL, Das R, Garrison J, Reisfeld RA, et al: Clinical and immune responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol 2000;18:376-384.
15. Vázquez AM, Alfonso M, Lanne B, Karlsson KA, Carr A, Barroso O, Fernández LE, Rengifo E, Lanio ME, Alvarez C, et al: Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids. Hybridoma 1995;14:551-556.
16. Moreno E, Lanne B, Vázquez AM, Kawashima I, Tai T, Fernández LE, Karlsson K-A, Ångström J, and Pérez R: Delineation of the epitope recognized by an antibody specific for N-glycolylneuraminic acid-containing gangliosides. Glycobiology 1998;8: 695-705.
17. Vázquez AM, Pérez A, Hernández AM, Macías A, Alfonso M, Bombino G, and Pérez, R: Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody. Hybridoma 1998;17:527-534.
18. Pérez A, Lombardero J, Mateo C, Mustelier G, Alfonso M, Vázquez AM, and Pérez R: Immunogenetic analysis of variable regions encoding Ab1 and γ-type Ab2 antibodies from the NeuGc-containing ganglioside family. Hybridoma 2001;20:211-221.
19. Carr A, Mullet A, Mazorra Z, Vázquez AM, Alfonso M, Mesa C, Rengifo E, Pérez R, and Fernández LE: A mouse monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 2000;19:241-247.
20. Carr A, Mesa C, Arango MC, Vázquez AM, and Fernández LE: In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody. Hybridoma and Hybridomics 2002;21:463-468.
21. Stults CLM, Sweeley CC, and Matcher BA: Glycosphingolipids: structure, biological source, and properties. Methods Enzymol 1989;179:167-214.
22. Hashimoto Y, Otsuka H, Sudo K, Susuki K, and Yamakawa T: Genetic regulation of GM2 expression in liver of the mouse. J Biochem 1983;93:895-901.
23. Svennerholm L: Ganglioside isolation. Methods Carbohydr Chem 1976;6:464-474.
24. Alfonso M, Vázquez AM, Carr A, Haerslev T, Fernández LE, Lanio ME, Alvarez C, Zeuthen J, and Pérez R: T cell-independent B cell response to self monosialogangliosides: primary response monoclonal antibodies. Hybridoma 1995;14:209-216.
25. Tormo BR, Gavilondo JV, Domínguez C, Freyre M, Rodríguez T, and Biberfeld P: CEA in colonic adenocarcinomas and precancerous lesions. An immunohistochemical study with a novel monoclonal antibody. APMIS 1989;97:1073-1080.
26. Vázquez AM, Tormo BR, Alfonso M, Velandia A, Fernández LE, Giscombe R, Ansotegui Y, Jeddi Tehrani M, Cedeño M, Toledo AL, et al: Characterization of ior C5 colorectal tumor associated antigen. Immunología 1995;14:130-132.
27. Bayer E, and Wilkek M: The use of avidin-biotin complex as a tool in molecular biology. Methods Biochem Anal 1980;26:1-45.
28. Raychaudhuri S, Saeki YS, Fuji H, and Köhler H: Tumor-specific idiotype vaccines. I. Generation and characterization of internal image tumor antigen. J Immun 1986;137:1743-1749.
29. Andrew SM, and Titus JA: Fragmentation of immunoglobulin G. In: Current Protocols in Immunology. Colligan JE, Kruisbeek AM, Margulies DH, Shevach EM, and Strober W (Eds.). Wiley, New York, 1997, pp. 2.8.1-2.8.10
30. Alfonso M, Vázquez AM, Carr A, Haerslev T, Fernández LE, Lanio ME, Alvarez C, Zeuthen J, and Pérez R: T-cell independent B cell response to self monosialogangliosides: primary response monoclonal antibodies. Hybridoma 1995;14:209-216.
31. Kawashima I, Ozawa H, Kotani M, Susuki M, Kawanu T, Gomobuchi M, and Tai T: Characterization of ganglioside expression in human melanoma cells: Immunological and biochemical analysis. J Biochem 1993;114:186-193.
32. Reitan SK, and Hannestad K: A syngeneic idiotype is immunogenic when borne by IgM but tolerogenic when joined to IgG. Eur J Immunol 1995;25:1601-1608.
33. Padlan EA: Anatomy of the antibody molecule. Mol Immunol 1994;31:169-217.
34. Wedemayer GJ, Patten PA, Wang LH, Schultz PG, and Stevens RC: Structural insights into the evolution of an antibody combining site. Science 1997;276:1665-1669.
35. Alfonso M, Díaz A, Hernández AM, Pérez A, Rodríguez E, Bitton R, Pérez R, and Vázquez AM: An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 2002;168: 2523-2529.
36. Vázquez AM, Gabri MR, Hernández AM, Alonso DF, Beausoleil I, Gómez DE, and Pérez R: Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides. Oncol Rep 2000;7:751-756.